Njomnang Soh P, Vidal F, Huyghe E, Gourdy P, Halimi J M, Bouhanick B
Groupe de Recherche en Fertilité Humaine EA 3694, Université Paul-Sabatier, 31059 Toulouse, France.
Département de gynécologie obstétrique, CHU Purpan, 1, place Baylac, 31059 Toulouse, France.
Diabetes Metab. 2016 Feb;42(1):16-24. doi: 10.1016/j.diabet.2015.07.002. Epub 2015 Aug 29.
Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium-glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes.
糖尿病是女性和男性发生泌尿道及生殖器感染的一个易感因素。钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类用于2型糖尿病（T2D）患者的新型治疗药物，已在欧洲的一些国家上市。它们主要通过作用于肾脏中的SGLT2减少肾葡萄糖重吸收，从而增加尿中葡萄糖排泄来降低血糖。总体而言，它们耐受性良好，但因其作用方式会导致特定的副作用以及生殖器（外阴炎和龟头炎）和泌尿道感染风险增加，而T2D患者本身就已面临较高风险，这些感染在治疗的前6个月内就有报道。通常这些感染事件可通过标准疗法成功治疗，但糖尿病专科医生并不习惯处理这些问题。本综述的目的是描述不同类型的下泌尿道和生殖器感染，以及目前针对糖尿病患者可用的治疗策略。
